Today, Green Valley Pharmaceutical Technology announced its official joining of the Alzheimer's Disease (AD) Precision Prevention and Treatment Alliance (hereinafter referred to as the "AD Precision Prevention and Treatment Alliance"), working together with the medical and industrial communities to contribute to the high-quality development of China's elderly dementia prevention and cognitive health industry. The Alzheimer's Disease Precision Prevention and Treatment Alliance is jointly initiated by the Precision Medicine Research and Industry Development Alliance and the Brain Health Action. By integrating the advantages of AD precision prevention and treatment in the two platforms, it constructs efficient communication channels with the government, researchers, clinical experts, and entrepreneurs, stimulates innovation vitality in the field of AD precision prevention and treatment, and jointly promotes the development of the entire chain of AD precision prevention and treatment. Recently, the "Alzheimer's Disease Precision Prevention and Treatment Ecological Innovation White Paper 2025" jointly led by the Alzheimer's Disease Precision Prevention and Treatment Alliance, the Chinese Brain Health Action Expert Committee, the Neurology Branch of the Chinese Medical Association, the Neurology Branch of the Chinese Medical Association, and the Brain Health Branch of the Chinese Stroke Association was held in Hangzhou. As a member of the core industry of the alliance and a supporter of writing and publishing white papers, Green Valley was invited to participate. Chen Xiaochun, Chairman of the AD Alliance, stated that the establishment of the "Alzheimer's Disease Precision Prevention and Treatment Alliance" marks a new stage of multi-party collaboration in AD prevention and control in China. The alliance will focus on promoting four major tasks in the near future: standardizing the construction of community brain health centers, training AD professionals, unifying screening standards, and strengthening science popularization and publicity. And plans to develop automated screening tools through AI technology, establish a nationwide AD queue database, and promote the translation of scientific research achievements into clinical practice. Li Jinhe, a Leffler Scholar at Harvard Medical School, Director of the Neuromedical Big Model Intelligence Joint Laboratory at Guangdong Institute of Intelligent Science and Technology, and CEO of Green Valley Pharmaceutical Technology, attended and participated in the roundtable discussion on "Future Development of AD Industry". He had in-depth discussions with leading representatives from industries such as Eisai, Roche Diagnostics, and Xiantong. Li Jinhe said, "The release of the white paper is of great significance. It is an important guide for connecting national policies and policy implementation. Patients will always be the starting point of all our work. Green Valley Pharmaceutical Technology focuses on exploring and applying the brain gut axis field, committed to improving human cognitive health, and looks forward to working with all sectors of the" prevention, screening, diagnosis, and treatment "chain to accelerate the integration process of AD precision prevention and treatment under the guidance of the AD Precision Prevention and Control Alliance, and to help achieve the national strategic goal of 'healthy aging' as soon as possible. Early screening and diagnosis of Alzheimer's disease is particularly important. Only by detecting these patients early can we have the opportunity to prevent or even reverse the development of the disease." In recent years, in order to meet the needs of patients who have not yet been treated, Green Valley Pharmaceutical Technology has deepened the integration of AD diagnosis and treatment. We will continue to make efforts in technological innovation and ecological synergy, Accelerate the promotion of the innovative ecological layout of "prevention screening, diagnosis and treatment of health" throughout the entire course of the disease, and strive to enhance the public's awareness of proactive early screening and diagnosis through the support of public welfare projects. Strive to provide personalized and intelligent cognitive health solutions for every patient, work together with all partners, serve the construction of the entire disease management system, lead the improvement of human cognitive health, and help achieve the 2030 "Three 80s" (awareness rate>=80%, initial screening rate>=80%, initial screening positive intervention guidance rate>=80%) goals. In February of this year, Green Valley Pharmaceutical Technology reached a strategic cooperation with Novozymes, aiming to help promote early intervention for Alzheimer's disease, explore its comorbidity mechanisms, accelerate the development of cutting-edge diagnostic and treatment technologies and innovative drugs, and benefit more patients. (New Society)